Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

ConforMIS

Elys Game Technology, Corp.

NexGen Energy

Protagenic Therapeutics

Senseonics Holdings

Sesen Bio Inc.

Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.

7 Best Penny Stocks to Buy Now for Potential 10X Gains

NEW YORK, June 23, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Maurizio Fava, a world-leading expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company's Scientific Advisory Board. Dr. Fava obtained his MD from the University of Padova School of Medicine where he completed residency training in endocrinology.

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

NEW YORK, June 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board. Dr. Bergethon is the Vice President and Head of Digital and Quantitative Medicine at Biogen Inc., where he leads the effort to transform clinical trials and humanize drug discovery by encouraging the transition of clinical trial measures from a qualitative to a quantitative discipline.

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

It offers a great way to tap into the psychedelics market -- but is it too risky of an investment right now?

Is Mind Medicine a Buy?

Cinedigm

1847 GOEDEKER INC.

Ideanomics Inc

Which penny stocks are investors watching following Powell's remarks and the Fed meeting? The post 4 Penny Stocks to Watch Following the Fed Meeting and Powell's Remarks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks to Watch Following the Fed Meeting and Powell's Remarks

Yes, but with the chance of great reward comes substantial risk.

Could Mind Medicine Be a Millionaire-Maker Stock?

The stock price of Mind Medicine (MindMed) Inc (NASDAQ: MNMD) increased by over 3% pre-market. This is why it happened.

MNMD Stock Price Increases Over 3% Pre-Market: Why It Happened

COMPASS Pathways

These psychedelic stocks have compelling product pipelines and have built up a great head of steam in the past month thanks to the PSY ETF. The post 3 Psychedelics Stocks Getting High Thanks to the Newly Launched PSY ETF appeared first on InvestorPlace.

3 Psychedelics Stocks Getting High Thanks to the Newly Launched PSY ETF

While MNMD stock is incredibly speculative due to uncertainties of psychedelic therapeutics, the need may transcend the risks. The post Mind Medicine Stock Might Still Be Worth the Risk Here appeared first on InvestorPlace.

Mind Medicine Stock Might Still Be Worth the Risk Here

Froth from its uplisting is having an impact.

Why Shares of MindMed Dropped 13% in May

Mind Medicine Inc. (NASDAQ:MNMD), more commonly known as MindMed, has announced co-founder and chief executive J.R. Rahn is stepping down from his leadership role, effective immediately.

J.R. Rahn Steps Down As MindMed CEO

NEW YORK, June 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company's co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect.

MindMed Announces Chief Executive Officer Transition

MNMD stock has immense potential, but the plethora of risks surrounding it limit its attractiveness at this time The post The Mind Medicine Stock Story Has an Awful Lot of Holes in It appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn't matter if you have $500 in savings or $5 million.

The Mind Medicine Stock Story Has an Awful Lot of Holes in It

Mind Medicine is a leading psychedelic pharmaceutical company and the first to be publicly listed. On Thursday, it became the first NEO-listed company to be included in an MSCI Index.

Stockwatch: MindMed Is Added To The MSCI Small Cap Canada Index

TORONTO--(BUSINESS WIRE)-- #MSCI--MSCI Inc. now recognizes NEO as an eligible market for inclusion in MSCI Indexes under the MSCI Global Investable Market Indexes Methodology.

NEO Exchange Announces Eligibility In MSCI Indexes

NEW YORK, May 27, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that each of the resolutions put before the annual and special meeting of shareholders held today (the "Meeting") was passed by the requisite majority of shareholders. As described in the Company's management information circular dated April 19, 2021 (the "Circular"), Jamon Alexander Rahn, Miriam Halperin Wernli, Stephen Hurst, Perry Dellelce, Bruce Linton and Brigid Makes were re-elected as directors of the Company.

MindMed announces shareholder Meeting Results

Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early.

Mind Medicine Stock Is Not a Trip To Take Just Yet

NEW YORK, May 26, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase 1 studies that each used a randomized, double-blind, placebo-controlled, crossover design and were conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland.

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

MindMed (NASDAQ: MNMD) and Israel-listed Nextage Therapeutics have entered into an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates. The agreement utilizes Nextage's Brain Targeting Liposome System (BTLS) delivery technology.

MindMed Collaborates with Nextage Therapeutics for Brain Targeting Liposome System

Allied Esports Entertainment Inc

Coty

Casper Sleep

Drive Shack

Ammo

Sirius XM Holdings Inc

While no one likes to see red ink on their portfolio, a key benefit is that you now have more choices regarding cheap stocks to buy. The post 7 Cheap Stocks to Buy Now Under $10 appeared first on InvestorPlace.

7 Cheap Stocks to Buy Now Under $10

NEW YORK, May 24, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the "MOU") regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license.  MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.

MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System

(Kitco News) - The day MindMed listed on the NASDAQ in late April, the share price more than doubled in one day from $2.73 a share to $5.80.

Why MindMed stock doubled in one day - JR Rahn

It has a shot of finding success. Yet, said success remains many years away.

The Jury's Still Out on Psychedelics Play MindMed Stock

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), announced Thursday that it had obtained authorization from the local Swiss ethics committee to conduct the first clinical trial on mescaline. What Happened The psychedelic medicine biotech company noted that the study will examine the effects of various “doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered state of consciousness.

MindMed To Conduct The First Modern Research On Mescaline In Switzerland

BASEL, Switzerland, May 20, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study). The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland, and is planned to start this month.

News for Mind Medicine MindMed Stock (MNMD)